<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc">eid</journal-id><journal-title>Emerging Infectious Diseases</journal-title><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9621190</article-id><article-id pub-id-type="pmc">2640153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rattan</surname><given-names>A.</given-names></name><email>rattan@medinst.ernet.in</email></contrib><contrib contrib-type="author"><name><surname>Kalia</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>N.</given-names></name></contrib></contrib-group><aff>Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.</aff><pub-date pub-type="ppub"><season>Apr-Jun</season><year>1998</year></pub-date><volume>4</volume><issue>2</issue><fpage>195</fpage><lpage>209</lpage><abstract><p>Multidrug-resistant strains of Mycobacterium tuberculosis seriously threaten tuberculosis (TB) control and prevention efforts. Molecular studies of the mechanism of action of antitubercular drugs have elucidated the genetic basis of drug resistance in M. tuberculosis. Drug resistance in M. tuberculosis is attributed primarily to the accumulation of mutations in the drug target genes; these mutations lead either to an altered target (e.g., RNA polymerase and catalase-peroxidase in rifampicin and isoniazid resistance, respectively) or to a change in titration of the drug (e.g., InhA in isoniazid resistance). Development of specific mechanism-based inhibitors and techniques to rapidly detect multidrug resistance will require further studies addressing the drug and drug-target interaction.</p></abstract></article-meta></front></article>